期刊文献+

抗心力衰竭药物的研究进展 被引量:5

下载PDF
导出
作者 史鲁秋 徐芳
出处 《中国药师》 CAS 2003年第7期406-408,共3页 China Pharmacist
  • 引文网络
  • 相关文献

参考文献19

  • 1江其生,胡德耀.新型钙增敏剂MCI-154研究现状及应用前景[J].国外医学(药学分册),2000,27(3):143-147. 被引量:5
  • 2傅毅.钙增敏剂类 心衰治疗药 左西孟坦(levosimendan)[J].国外医药(合成药.生化药.制剂分册),2001,22(5):316-316. 被引量:15
  • 3Cadiotonic/Phosphodiesterase Inhibitor : OPC - 18 7 9 0 ( toborinone )[J]. Drugs of the Future, 1997, 20(12) : 1288.
  • 4MacGowan GA, Haber HL, Cowart TD, et al. Direct myocardial effects of OPC-18790 in human heart failure: beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis[J]. J Am Coll Cardiol, 1998, 31(6) : 1344-1351.
  • 5Anon. Phosphodiesterase Inhibitor: Toborinone[J]. Pharma. Projects: Therapeutic, 2002, Cardiostimulant a445.
  • 6Abraham WT, Lowes BD, White M, et al. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure[J]. J Card Fail, 1994,1(1) :57-62.
  • 7Changbin, Chang-Shen, Patrick, et al. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure [ J ]. Original Research,2001, 22(6) : 541-548.
  • 8Dingemanse J, Clozel M, Van Giersbergen PL. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist[J]. J Cardiovasc Pharmaco1,2002,39( 6 ) : 795-802.
  • 9Cotter G, Kiowski W, Kaluski E, et al. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrese in blood pressure in patients with congestive heart failure[J]. Eur J Heart Fail, 2001,3(4) : 457-461.
  • 10Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan,an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study[J]. Chest, 2002, 121(6) : 1860-1868.

二级参考文献4

  • 1董林旺,佟利家,张力,苏静怡,唐朝枢.败血症休克时心肌和心肌线粒体钙转运的变化[J].生理学报,1993,45(2):158-163. 被引量:8
  • 2胡德耀,梅建民,殷作明,刘良明,卢儒权,陈惠孙.MCI-154抗休克作用及其改善心功能的机理[J]中国病理生理杂志,1998(03).
  • 3陈修等.心血管药理学[M]人民卫生出版社,1997.
  • 4金惠铭.病理生理学[M]人民卫生出版社,1996.

共引文献17

同被引文献34

  • 1陈化,王登科,刘秀梅.厄贝沙坦与培哚普利治疗老年慢性心力衰竭疗效的对比研究[J].中华老年多器官疾病杂志,2002,1(3):197-199. 被引量:3
  • 2葛海霞,王礼琛.2(1H)-喹啉酮类化合物的药理活性及构效关系[J].药学进展,2005,29(7):309-316. 被引量:15
  • 3胡德耀 梅建民 殷作明 等.MCI-154抗休克作用及其改善心功能的机理[J].中国病理生理学报,1998,14(3):328-328.
  • 4Motte S,McEntee K,Naeije R.Endothelin receptor antagon-ists.Pharmacology&Therapeutics,2006,110 : 386.
  • 5Dhaun N,M.Pollock D,Goddard J.et al.Selective and mixed endothelia receptor antagonism in cardiovascular diseases.TRENDS in Pharmacological Sciences,2008,28(11) : 574.
  • 6金炜 朱彦琪.口服levosimendan改善严重充血性心力衰竭患者的心脏功能和血流动力学[J].国外医学·心血管分册,2000,27(2):115-115.
  • 7Nadler G,Delimoge I.Stereospecificity of myofibrillar [4-(sub-stituted-amino)phenyl] calcium sen-sitivity and PDE inhibition in cardiotonic thiadiazinones [ J ].Eur J Med Chem,1996,31(10):805-812.
  • 8Endoh M.Mechanisms of action of novel cardiotonic agents[J].J Cardiovasc Pharmacol,2002,40 (3):323-328.
  • 9Hasenfus G.Effects of calcium sensitizer on intracellular calcium handing and myocardial energyetics [ J ].J Cardiovasc pharmacol,1995,261:45-51.
  • 10Brixius K,Hoischen S,Zobel C,et al.The Ca^2+sensitizers 0GP48506and EMD-57O33,but not the Na^+channel modulator BDF 9148,prolong contractile twitch in guine pig cardiomyocyte[J].ZKardiol,2001,90(4):286-291.

引证文献5

二级引证文献8

;
使用帮助 返回顶部